Kapitalforeningen Accunia Invest
Bestyrelsen i Kapitalforeningen Accunia Invest har godkendt nedennævnte udlodninger for fjerde kvartal af 2020. Udlodningerne vil formelt set blive endeligt godkendt på foreningens ordinære generalforsamling.
De optjente udbytter er vist i nedenstående tabel. Tallene er beregnet pr. 31. december 2020 og opgjort i kr. pr. investeringsbevis.
| ISIN | Kortnavn | Andelsklasse/afdeling | DKK/andel |
| DK0060804136 | ACACIGDKK | European CLO Investment Grade | 5 |
| DK0060804052 | ACAECO | European CLO Opportunity KL | 13 |
| DK0061149036 | ACKEHY | European High Yield KL | 15 |
Tidsplan
22. januar 2021 Sidste dag for handel med beviser inkl. udbytte for 4. kvartal 2020
25. januar 2021 Udbyttet fragår, og investeringsbeviserne handles uden udbytte for 4. kvartal 2020
27. januar 2021 Udbyttet er til disposition på investors konto
Kontaktperson(er):
Direktør Caspar Møller, tlf. +45 3332 7070.
Yderligere oplysninger om Kapitalforeningen Accunia Invest findes på www.accunia.com.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Ecorobotix SA8.11.2025 12:15:00 CET | Press release
Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica
IOT Squared8.11.2025 11:00:00 CET | Press release
Saudi “Emerge” Emergency and Crisis Resilience Platform Named Among the World’s Best Smart City Solutions in the 2025 Smart City Awards
Novo Nordisk A/S8.11.2025 09:18:56 CET | Press release
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Columbus A/S7.11.2025 23:46:30 CET | Press release
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom